



Accelovance, Inc. is Prepared to Meet Emerging Needs for Zika Virus Research

ROCKVILLE, MD – February 11, 2016 – Accelovance, Inc. (Accelovance), a global contract research organization (CRO) focusing in vaccines, oncology, and general medicine announced today it is well positioned with staff and clinical facilities to support upcoming research needs associated with the Zika virus.

“Accelovance has a strong heritage in vaccine research, especially with pandemic indications similar to Zika. Over the last 10 years we have helped Pharmaceutical Sponsors and the U.S. Government advance pandemic research and prevention measures in such areas as H1N1, H5N1, H7NP, Dengue, and Ebola” said Stephen J. Trevisan, President and CEO of Accelovance.

In a recent interview Dr. Anthony Fauci, head of the National Institute of Allergy and Infectious Diseases (NIAID), publicly noted, “I’ve made it clear that we want to put a full-court press. I’m saying, ‘Folks, this is it, all hands on deck for Zika, this is really important.’ We are rapidly pushing.”

In order to meet the anticipated upcoming research needs for Zika, Accelovance offers Pharmaceutical Sponsors and the U.S. Government a strong research partner in vaccine development. Trevisan noted, “Through the combination of our vaccine experienced staff, a strong history of partnership in previous pandemic research, our ability to leverage our integrated research centers, and our strategic alliance with FHI 360 and their staff coverage in the currently affected areas, Accelovance is the only organization capable of providing a truly complete research solution for Zika. We are eager to align our comprehensive approach with Pharmaceutical Sponsors and the U.S. Government to advance treatment and prevention of this potential pandemic.”

About Zika Virus

The Zika virus, a member of the *Flaviviridae* virus family, is spread to people through mosquito bites. The virus was first isolated in Uganda and is demonstrated to cause symptoms including fever, rash, joint pain, and conjunctivitis. While the illness is usually mild, recent outbreaks in South America (especially Brazil) have resulted in birth related defects including microcephaly. As the virus has spread to 27 countries, on 01 February 2016 the World Health Organization (WHO) declared it a global public health emergency.

About Accelovance

Accelovance, Inc., headquartered in Rockville, MD, is an industry award-winning global Contract Research Organization (CRO) focused primarily in vaccine, oncology, and general medicine clinical research. As a clinical services provider to the pharmaceutical and biotechnology industries, Accelovance offers comprehensive clinical development services including management and implementation of Phase I-IV clinical trials, supportive research centers, and a clinical engagement solution utilized for recruitment, post-marketing surveillance, and long-term survival follow-up. For more information, visit the company’s Web site at www.accelovance.com.

###

Press Contact: Michael Keens, VP Business Development
240.238.4941
mkeens@accelovance.com
Twitter: @Accelovance